Five-year data show excellent outcomes for female and small annulus patients with edwards tavr

New york--(business wire)--edwards lifesciences (nyse: ew) today announced the results from an analysis of data from the partner trials examining outcomes of transcatheter aortic valve replacement (tavr) patients with a small annulus. through five-year follow up of more than 1,300 low and intermediate risk sapien 3 valve patients there were excellent clinical outcomes and valve durability irrespective of the patient's annulus size or sex. these data were presented during the late-breaking clini.
EW Ratings Summary
EW Quant Ranking